PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ: PMVP · Real-Time Price · USD
1.520
+0.030 (2.01%)
Oct 9, 2026, 4:00 PM EDT - Market closed
PMV Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 12.47 | 37.98 | 40.88 | 37.71 | 108.3 | 172.47 |
Short-Term Investments | 66.96 | 74.96 | 128.58 | 165.35 | 132.76 | 124.7 |
Cash & Short-Term Investments | 79.43 | 112.94 | 169.45 | 203.06 | 241.05 | 297.16 |
Cash Growth | -44.17% | -33.35% | -16.55% | -15.76% | -18.88% | -17.78% |
Prepaid Expenses | 1.98 | 2.28 | 6.2 | 3.53 | 5.13 | 3.3 |
Restricted Cash | - | - | - | 0.82 | 0.82 | 0.82 |
Total Current Assets | 81.41 | 115.23 | 175.66 | 207.41 | 247.01 | 301.29 |
Property, Plant & Equipment | 0.36 | 1.04 | 1.55 | 19.05 | 20.49 | 13.15 |
Long-Term Investments | - | - | 13.84 | 25.51 | 2.5 | 16.91 |
Other Long-Term Assets | 0.3 | 0.3 | 0.24 | 0.19 | 0.31 | 0.22 |
Total Assets | 82.07 | 116.56 | 191.29 | 252.15 | 270.31 | 331.57 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.02 | 3.16 | 6.58 | 3.24 | 3 | 3.19 |
Accrued Expenses | 8.33 | 7.86 | 7.44 | 9.94 | 7.31 | 8.63 |
Current Portion of Leases | 0.22 | 0.4 | 0.35 | 0.85 | 0.53 | 0.4 |
Total Current Liabilities | 10.57 | 11.42 | 14.37 | 14.03 | 10.83 | 12.22 |
Long-Term Leases | - | 0.44 | 0.84 | 12.43 | 13.45 | 10.79 |
Total Liabilities | 10.57 | 11.85 | 15.21 | 26.46 | 24.28 | 23.01 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Additional Paid-In Capital | 554.16 | 551.08 | 544.65 | 535.47 | 487.52 | 476.36 |
Retained Earnings | -482.58 | -446.45 | -368.71 | -310 | -241.04 | -167.73 |
Comprehensive Income & Other | -0.08 | 0.08 | 0.14 | 0.22 | -0.45 | -0.08 |
Total Common Equity | 71.5 | 104.71 | 176.08 | 225.69 | 246.03 | 308.56 |
Shareholders' Equity | 71.5 | 104.71 | 176.08 | 225.69 | 246.03 | 308.56 |
Total Liabilities & Equity | 82.07 | 116.56 | 191.29 | 252.15 | 270.31 | 331.57 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.22 | 0.84 | 1.19 | 13.29 | 13.98 | 11.19 |
Net Cash (Debt) | 79.21 | 112.11 | 182.11 | 215.28 | 229.57 | 302.88 |
Net Cash Growth | -46.22% | -38.44% | -15.41% | -6.23% | -24.20% | -16.20% |
Net Cash Per Share | 1.49 | 2.13 | 3.53 | 4.48 | 5.04 | 6.71 |
Filing Date Shares Outstanding | 53.46 | 53.33 | 51.93 | 51.44 | 45.77 | 45.45 |
Total Common Shares Outstanding | 53.46 | 53.33 | 51.94 | 51.45 | 45.77 | 45.43 |
Working Capital | 70.84 | 103.81 | 161.29 | 193.38 | 236.17 | 289.07 |
Book Value Per Share | 1.34 | 1.96 | 3.39 | 4.39 | 5.38 | 6.79 |
Tangible Book Value | 71.5 | 104.71 | 176.08 | 225.69 | 246.03 | 308.56 |
Tangible Book Value Per Share | 1.34 | 1.96 | 3.39 | 4.39 | 5.38 | 6.79 |
Machinery | 1.46 | 1.48 | 1.82 | 3.17 | 2.53 | 2.28 |
Leasehold Improvements | 0.05 | 0.08 | 0.05 | 10.77 | 0.41 | 0.16 |